HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
Last updated: 2026-11-19 17:25:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Alpha Tau Medical Ltd. (DRTS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $11.14, with a market capitalization of $1.12B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.43 to $15.79. This page covers its latest market performance, valuation, price trends and company information.
$1.12B | |
$12.08 | |
$12.21 | |
$10.94 | |
$12.01 | |
858.93K | |
581.81K | |
-- | |
$15.79 | |
$3.43 | |
-- | |
2026-06-30 |
Alpha Tau Medical Ltd. (DRTS) is currently trading at $11.14 as of 2026-11-19 17:08:55, down 8.16% ($0.98) from the previous close of $12.01
During today's regular trading session, DRTS has traded between $10.94 and $12.21, with a trading volume of 858.93K shares. The current price is near the lower end of today's range.
Over the past seven days, Alpha Tau Medical Ltd. (DRTS) moved from $13.70 to $11.14, representing a decline of 18.69% ($2.56).
The stock traded between $10.94 and $14.59 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 899.59 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 62.4%
DRTS is currently trading at $11.14, placing it 62.4% of the way from its 52-week low of $3.43 to its 52-week high of $15.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
| Employees | 121 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Alpha Tau Medical Ltd. and DRTS stock.
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
Alpha Tau Medical reports a 100% objective response rate and strong safety in interim U.S. REGAIN glioblastoma trial data.
Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS) stock rose
Take-Two rose 4% ahead of GTA VI’s Nov. 19 release on strong presales. GreenPower led gainers, while Datavault AI plunged 43%.
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6
Eligible investors can buy real shares of Alpha Tau Medical Ltd. (DRTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to DRTS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between DRTS shares and USD.
DRTS Shares to USD
1.00 DRTS shares = 11.14 USD
Calculations are estimates based on the latest available price and are for reference only.